HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

GLP-1 drugs and intensive dieting cause similar lean-mass loss (about 20-26%)

Louis Nervegna · May 31, 2026 · ♥ 4 reactions · 0 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Weight, visceral & liver fatExercise & fitness
AI summary & key facts

Shared summary of a 2026 meta-analysis in Diabetes, Obesity and Metabolism: the share of weight lost as lean mass is broadly comparable for semaglutide, tirzepatide and intensive lifestyle intervention. The fix is resistance training, adequate protein and body composition monitoring.

#glp1HD #muscleHD #weightlossHD

Research cited

GLP-1 drugs don’t steal your muscle. Weight loss does.
A 2026 meta-analysis in Diabetes, Obesity and Metabolism compared lean mass changes between GLP-1 drugs and intensive lifestyle intervention in adults with overweight or obesity. The finding: the proportion of weight lost as lean mass is broadly comparable between the two approaches — roughly 20–26% regardless of whether you’re on semaglutide, tirzepatide, or dieting hard.
The concern about muscle loss on these drugs is real. But it’s a weight loss problem, not a drug problem.
The fix is the same either way: resistance training, adequate protein, and body composition monitoring. Not doing those things — whether you’re on a GLP-1 or not — is where the muscle goes. 💬 Comment NEWSLETTER below and we’ll send you all the details of our free weekly newsletter — evidence-based cardiology and metabolic health, every week.

No photo description available.No photo description available.No photo description available.No photo description available.No photo description available.
← newer: Daraxonrasib raised 1-year survival from 18.7% to 53.3% in polder: Statin-intolerant? Options include ezetimibe, bempedoic acid →